Experimental Obesity Drug Beats Placebo Again

	Tweet

The experimental weight-loss drug lorcaserin may spur modest weight loss without the heart risks of some older drugs, a new clinical trial confirms - though whether the medication will ever reach the market remains up in the air.

Last October, the U.S. Food and Drug Administration (FDA) declined to approve lorcaserin as an obesity treatment, citing research in rats that suggested there could be a cancer risk.

This latest study, reported in the Journal of Clinical Endocrinology and Metabolism, backs up earlier research showing that lorcaserin can shave off some extra pounds.

Of 4,000 obese adults who used the drug for a year, more than 40 percent lost at least 5 percent of their initial weight - versus a quarter of those given placebo pills who lost that much.

And the drug facilitated weight loss without raising the risk of heart-valve damage, according to the findings.

Reports of fatal heart-valve problems are what caused the infamous diet drug known as ”fen-phen” to be pulled from the market in 1997.

Still, it’s unclear whether lorcaserin will ultimately play any role in the battle against obesity, which now affects about one-third of U.S. adults.

The drug’s maker, Arena Pharmaceuticals Inc, has said it will conduct further research into the potential cancer risk. Arena’s new drug application to the FDA is still considered “open” while the company gathers data to answer the agency’s remaining questions about lorcaserin.

Drugmakers have struggled for years to develop weight-loss drugs that are both effective and safe.

Like fen-phen before it, another diet drug - Meridia - was pulled from the U.S. market last year after being linked to heart problems in some users.

And lorcaserin is one of three experimental obesity drugs rejected by the FDA in the past year over safety concerns. The other two are Orexigen Therapeutics’ Contrave, which combines the antidepressant bupropion with naltrexone, a drug used to fight alcohol and drug addiction; and Vivus Inc’s Qnexa, a combination of the appetite suppressant phentermine and the anti-seizure drug topiramate.

The FDA wanted more data on the two drugs’ potential heart risks.

Lorcaserin is believed to work by targeting a brain receptor for the chemical serotonin that is associated with hunger.

In a study published last year in the New England Journal of Medicine, researchers at Arena found that of 1,600 obese adults given lorcaserin for a year, 47.5 percent lost at least five percent of their body weight. Of that group, 68 percent kept the weight off for a second year.

That beat the placebo group, in which 20 percent shed that much weight after a year. (Both groups made lifestyle changes along with taking pills.)

RELATED STORIES:
Weight in pregnancy best controlled by diet, study shows   FDA advisers recommend approving weight loss drug   Bridal Hunger Games   Exercise, Group Support Work for Weight Loss   Misperception of weight is an important barrier to weight loss   Obesity drugs need heart studies, U.S. advisers say   Weight Loss Surgery and Diabetes: Expert Interview Opportunity   New evidence on effects of green coffee beans in weight loss   Chocolate lovers tend to weigh less: study   Weight loss won’t necessarily help teen girls’ self-esteem   How to Best Help Your Child Lose Weight: Lose Weight Yourself   Qnexa: Is the new anti-obesity drug too risky?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]